Thematic Exposure -- 8/10
ResMed is the clear #1 in the global sleep apnea / respiratory care market — a structurally
undersupplied, demographically driven medical-device duopoly augmented by an out-of-hospital SaaS
layer. It holds ~48% global (and above 55% US) sleep-apnea device share, cemented when Philips exited
the US market on its 2021 recall. The core hardware business (88% of revenue) is both the dominant
mix and the faster grower (~11.5% YoY). Passes the oligopoly hard gate cleanly. Misses a 10 only
because devices sit at ~48% (not above 50%) global share and the ~12% SaaS sliver is competitive.
Weight: 35%
Sleep Apnea / Respiratory Care -- Strong, Durable Theme
Secular Tailwind -- Multi-Year Visibility
ResMed is a structural beneficiary of a massively undersupplied TAM: 80%+ of obstructive sleep
apnea remains undiagnosed globally, so the binding constraint is diagnosis/awareness, not
competition. That protects pricing and growth for the category leader. GLP-1 weight-loss drugs,
widely feared as a substitute, are shown by management data to expand the diagnosed funnel and
lift CPAP adherence — a tailwind, not a threat.
Clear #1 -- A Duopoly Turned Near-Monopoly in the Core
Oligopoly Gate: PASS
ResMed and Philips together controlled 80%+ of the global sleep-apnea device market. Philips'
2021 Respironics recall and multi-year US absence handed ResMed ~48% global / above-55% US device
share and a multi-year installed-base land grab in masks. This is a ≤3-player oligopoly (ResMed
+ Philips ± F&P) controlling 70-80% of the core hardware market — well above the gate threshold.
Recurring Resupply Annuity -- Sticky, High-Margin
Masks & Accessories -- Razor/Blade Lock-In
Masks and accessories (~37% of revenue) are consumables tied to the installed device base — a
razor/blade annuity that competitors cannot dislodge without first winning the device. Combined
with clinical validation, payor/competitive-bidding entrenchment, and Philips' continued US
absence, switching is slow and costly. ResMed is a price-setter in devices and masks.
Residential-Care SaaS -- Competitive, Lower-Share
SaaS (~12% of Revenue) -- The Fragmented Segment
The Residential Care Software segment (Brightree, MatrixCare) is top-tier in home-health/HME
software, but it is the most fragmented part of the portfolio (top-5 vendors = ~45% of
out-of-hospital software) with more competitive pricing pressure. At only ~12% of revenue it does
not drive the moat — the economically dominant hardware segments are concentrated, not fragmented.
Segment / Product-Line Mix (latest reported, cal 2026Q1)
| Segment / Product Line | Revenue | % Rev | Market Position |
|---|---|---|---|
| Devices (PAP flow generators) | $735.7M | 51.4% | ~48% global (#1; above 55% US post-Philips) |
| Masks & accessories | $524.8M | 36.7% | #1 globally; ResMed + F&P + Philips ~60% of mask market |
| Sleep & Respiratory Care (total) | $1,260.5M | 88.1% | ~48% device / #1 mask |
| SaaS (Residential Care Software) | $170.9M | 11.9% | Top-tier; top-5 vendors = ~45% (fragmented) |
| Total revenue | $1,431.4M | 100% | — |
The core hardware business is both the dominant mix (88%) and the faster grower: Sleep & Respiratory Care grew ~+11.5% YoY (from $1,130.6M in cal 2025Q1 to $1,260.5M), versus SaaS ~+6% YoY (from $161.2M to $170.9M).
Oligopoly Hard Gate
| Criterion | Result |
|---|---|
| ResMed share in core sleep-apnea devices | ~48% global / above 55% US |
| Any segment above 30% share? | Yes (devices, masks) |
| ≤3 players controlling above 70%? | Yes (ResMed + Philips ± F&P) |
| Customer could switch within 12 months? | No — device + resupply lock-in |
| Gate result | PASS |
8/10 — A textbook "leader in a growing
market" name: ~48% global / above-55% US share of the sleep-apnea device market, the #1 mask
franchise, and a recurring resupply annuity, all inside a ≤3-player oligopoly that became
near-monopolistic in the US after Philips' recall. The core hardware business (88% of revenue,
~11.5% YoY) is both the dominant mix and the faster-growing one, riding a structurally undersupplied
TAM with GLP-1s as a funnel tailwind. It misses a 10 only because devices (51% of revenue) sit at
~48% rather than above 50% global share, theme growth is solidly above-GDP but not cleanly above 10%
organic, and the ~12% SaaS segment is genuinely competitive and lower-share.
Data sourced from Daloopa (company_id 549) and earnings transcripts (FY2025 Q1 - FY2026 Q2).